Catyalyst Pharma (CPRX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Piper Jaffray Sees 'Transformational' Next 12 Months for Catalyst Pharmaceutical (CPRX)
August 11, 2015 11:05 AM EDTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and $7 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) after the company 2Q15 financials and a pipeline update, ending with $67.4M in cash.
"These resources should fully fund operations through Firdapse NDA approval and... More

